Upper Limb · 4 min read
Dupuytren's Disease: From Palm to Person — A Whole-Patient Approach
Dupuytren's disease changes a hand, but it affects a person. The patient who can no longer shake hands confidently, grip a racket, fasten a button, or play a musical instrument has lost something that extends beyond anatomy. Understanding that experience is the starting point for excellent care.
Dupuytren's disease — the progressive fibroproliferative condition of the palmar fascia that leads to digital flexion contracture — has a remarkable history that reflects centuries of observation, a Nobel-adjacent eponym, and, in recent decades, a genuine transformation in treatment options that has given patients more choice and better outcomes than any previous generation of those affected by the condition.
The genetics and biology behind the disease
Dupuytren's disease has a strong genetic component: first-degree relatives of affected individuals have a significantly elevated risk of developing the condition. It is most prevalent in people of Northern European descent, affecting approximately 3–4% of the general population and rising steeply with age. Associated conditions — diabetes mellitus, epilepsy (historically linked to phenytoin use), alcohol-related liver disease, and Peyronie's disease — provide clues to the systemic fibroproliferative biology underlying what appears to be a localised hand condition.
The pathological process — activation of myofibroblasts that lay down disorganised, contracted collagen — is shared with other fibrotic diseases, and the cellular biology is an active area of research. Understanding this biology illuminates why recurrence after any form of treatment is not a failure but a feature of the underlying disease process — one that must be communicated clearly to patients as part of any pre-treatment discussion.
A new era of treatment choice
For most of the 20th century, surgery — specifically open partial fasciectomy — was the only meaningful treatment option. The development of percutaneous needle fasciotomy as a minimally invasive technique, and the introduction of collagenase clostridium histolyticum injection as the first pharmacological treatment, have transformed the options available to patients.
Each modality has its place: needle fasciotomy for isolated, cord-like contractures in older patients or those where surgery carries elevated risk; collagenase injection for cord-dominant disease where the anatomy suits injection; open surgery for complex multi-cord, multi-digit disease, PIP joint contractures, and situations where recurrence after previous treatment must be addressed. The decision between modalities is reached through shared discussion, not algorithmic allocation.
In Dupuytren's disease, the right treatment is the one that addresses this patient's functional goals, disease characteristics, and life context — not the one that any surgeon happens to prefer.
The most gratifying outcomes in Dupuytren's surgery are those where a patient who has avoided seeking help because they "didn't want surgery" discovers that a less invasive option can restore their function without the recovery they feared. That conversation — which requires a surgeon who offers the full range of options — is one of the most rewarding in hand surgery.
💬 Patients with Dupuytren's often wait longer than they need to before seeking treatment. What are the most common reasons for delay that you encounter — and how do you address them?